Vallon Pharmaceuticals, Inc. (VLON) News
Filter VLON News Items
VLON News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
VLON News Highlights
- VLON's 30 day story count now stands at 6.
- Over the past 20 days, the trend for VLON's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
Latest VLON News From Around the Web
Below are the latest news stories about Vallon Pharmaceuticals Inc that investors may wish to consider to help them evaluate VLON as an investment opportunity.
Vallon Pharmaceuticals Reports Fiscal Year 2021 Financial Results and Provides Business Update- T opline data for p ivotal abuse study of the C ompany’s lead investigational program ADAIR expected this quarter |
Vallon Pharmaceuticals reports FY resultsVallon Pharmaceuticals press release (VLON): FY 2021 Net loss was $9.3M.Cash, cash equivalents and marketable securities of ~$7.5M |
Even with Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) stock down 13% this week, insiders who bought recently netted around US$20kVallon Pharmaceuticals, Inc. ( NASDAQ:VLON ) insiders who acquired shares over the previous 12 months, can probably... |
Vallon Pharmaceuticals to Present at the Virtual Investor 2022 Top Picks Conference– Live video webcast presentation on Tuesday, January 25th at 9:00 AM ET PHILADELPHIA, PA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, today announced that David Baker, President and Chief Executive Officer will present at the Virtual Investor 2022 |
Vallon Pharmaceuticals Presents New Data from Adult Stimulant Abuse Pattern Survey at the APSARD 2022 Annual Conference- Survey results reinforce existing literature that immediate-release (IR) amphetamines, such as Adderall®, are the most commonly abused preparation of prescription stimulants - Company’s abuse-deterrent stimulant formulations have the potential to address misuse and abuse of stimulant medication by non-oral routes, such as snorting - Pivotal abuse study of the Company’s lead investigational program ADAIR completed enrollment and dosing with topline data expected this quarter PHILADELPHIA, PA, J |
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th\- Access the event and schedule of presenting companies at virtualinvestorco.com -\- Live video webcast presentations of participating companies followed by interactive Q&A session -PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 /JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022. |
Vallon Pharmaceuticals to Present at the H.C. Wainwright BioConnect ConferencePHILADELPHIA, PA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders, announced today that David Baker, President & Chief Executive Officer of Vallon will present at the virtual H.C. Wainwright BioConnect Conference, taking place January 10-13, 2022. A vid |
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gamida Cell (GMDA), Ortho Clinical Diagnostics Holdings (OCDX) and Vallon Pharmaceuticals (VLON)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gamida Cell (GMDA – Research Report), Ortho Clinical Diagnostics Holdings (OCDX – Research Report) and Vallon Pharmaceuticals (VLON – Research Report). Gamida Cell (GMDA) In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Gamida Cell, with a price target of $22.00. The company's shares closed last Thursday at $2.40, close to its 52-week low of $2.10. According to TipRanks.com, Bernardino is a 5-star analyst with an average return of -17.5% and a 25.8% success rate. |
Vallon Pharmaceuticals Announces Achievement of Last Patient Last Visit in Pivotal SEAL Study for Lead Program, ADAIR- Topline results f ro m p ivotal SEAL study expected in Q1 2022 |
Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) Sees Large Growth in Short InterestVallon Pharmaceuticals, Inc. (NASDAQ:VLON) was the recipient of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 727,400 shares, a growth of 496.7% from the November 15th total of 121,900 shares. Currently, 22.7% of the company’s stock are short sold. Based on an average […] |